Complications arising from abnormal immune responses are the major causes of mortality and morbidity in diabetic patients. 
INTRODUCTION
Diabetic retinopathy, nephropathy, neuropathy and cardiovascular disease are complications that are major causes of mortality in patients with diabetes. 1 Inflammatory and immunologic abnormalities are involved in both type 1 and type 2 diabetes (T1D and T2D), as well as their associated complications. 2, 3 Hyperglycemic crises are associated with an elevation of counter-regulatory hormones and proinflammatory cytokines, markers of lipid peroxidation and oxidative stress. Patients with T2D and hyperglycemia have increased proinflammatory cytokines and activated innate immune cells and T cells, which are involved in cellular and/or humoral immune responses. [4] [5] [6] [7] 
CD4
1 CD25 1 T regulatory cells (Tregs) play pivotal roles in controlling immune balance and maintaining immune tolerance. There are two main subgroups of CD4 1 CD25 [10] [11] [12] whereas others have found an increase in Foxp3 mRNA or no change in the frequency of CD4 1 CD25 1 Tregs at the onset of diabetes. [13] [14] [15] The function of CD4 1 CD25 1 Tregs was decreased or remained unchanged in patients with T1D and diabetic NOD mice.
unclear whether hyperglycemia and/or genetic regulation caused the changes in CD4
1 CD25 1 Tregs observed in the spontaneous diabetes model, NOD mice or diabetic patients. NOD mice are potentially immune deficient due to intrinsic defects in their genome. In addition to autoimmune diabetes, they are prone to developing multi-organ autoimmune diseases such as autoimmune sialitis, thyroiditis and peripheral polyneuropathy. [20] [21] [22] Therefore, NOD mice are not suitable for studying the direct effect of hyperglycemia or other diabetes-induced alterations on the immune system and immunity. In this study, in order to address whether diabetes itself can impact the level and function of CD4 
MATERIALS AND METHODS

Mice
Six-to eight-week-old C57BL/6 (B6, H-2 b ) mice and BALB/c (H-2 d ) mice were purchased from the Beijing Experimental Animal Center (Beijing, China). Foxp3-green fluorescent protein (GFP) knock-in mice (H-2 d ) were kindly provided by Dr Bin Wang (Chinese University of Agriculture). All mice were maintained in a specific, pathogen-free facility and were housed in microisolator cages containing sterilized food, bedding and water. All experimental manipulations were performed in accordance with the Institutional Guidelines for the Care and Use of Laboratory Animals.
Diabetes induction, monitoring and insulin treatment
Six-to eight-week-old male C57BL/6 (B6) mice were injected intraperitoneally for 5 consecutive days with 40 mg/kg STZ (SigmaAldrich, St Louis, MO, USA) in citrate buffer (pH 4.5) to induce diabetes. Control B6 mice received vehicle buffer alone. Day 1 was defined as the day of the first STZ injection. Insulin injections (10 U/ kg, twice a day) were started 1 week after STZ administration. Blood samples were obtained from the tail vein to detect glucose levels using a glucose meter (Hypoguard, Minneapolis, MN, USA). Mice with a glucose level of greater than 11 mM for 2 consecutive weeks were considered to be diabetic. Glucose levels were monitored in diabetic mice twice a month following the initial diagnosis of diabetes.
Monoclonal antibodies (mAbs) and chemical reagents
The following mAbs were purchased from eBiosciences (San Diego, CA, USA): FITC-anti-mCD4 mAb (RM4-5, rat IgG2a), PE-CY5-antimCD4 mAb (H129.19, rat IgG2a), PE-anti-mCD4 mAb (RM4-5, rat IgG2a), FITC-anti-mCD8a mAb (53-6.7, rat IgG2a), PE-anti-mCD8a mAb (53-6.7, rat IgG2a), FITC-anti-mCD25 mAb (7D4, rat IgM), PE-anti-mCD25 mAb (PC61.5, rat IgG1), PE-CY5-anti-mCD25 mAb (PC61.5, rat IgM), PE-anti-mCD44 mAb (IM7, rat IgG2b), PE-anti-mCD45RB mAb (16A, rat IgG2a), PE-anti-mCD62L mAb (SK11, rat IgG2a), PE-anti-mGITR mAb (DTA-1, rat IgG2b), PEanti-mCD152 mAb (BNI3, mouse IgG2a), PE-anti-mFoxp3 mAb (FJK-16s, rat IgG2a), FITC-anti-mIFN mAb (XMG1.2, rat IgG1), FITC-labeled rat IgG2a and PE-labeled rat IgG2a. The following mAbs were purchased from Biolegend (San Diego, CA, USA): FITC-anti-h/mHelios mAb (22F6, hamster IgG), PE-anti-mIL-17A mAb (TC11-18H10.1, rat IgG1) and PE-anti-mIL-2 mAb (C15.6, rat IgG1). In addition, PE-anti-mCD8 mAb (53-6.7, rat IgG2a) and purified anti-mCD28 mAb (37.51) were obtained from BD Biosciences Pharmingen (San Diego, CA, USA) and mitomycin C (C 15 H 18 N 4 O 5 ) was obtained from Kyowa Hakko Co., Ltd (Tokyo, Japan). Transforming growth factor (TGF)-b and purified anti-CD3 mAb were obtained from R&D Co., Ltd (Minneapolis, MN, USA). DELFIA proliferation kit was purchased from PerkinElmer Co., Ltd (Wellesley, MA, USA).
Flow cytometry (FCM) assay
Approximately 30 000 cells (thymocytes, peripheral blood lymphocytes, splenocytes or lymphocytes) were freshly prepared and incubated with 2.4G2 to block FcRs, and then incubated with the indicated mAbs for 30 min at 4 uC in the dark. Cells were washed with FCM buffer (phosphate-buffered saline, pH 7.2, containing 0.1% NaN 3 and 0.5% bovine serum albumin). For intracellular staining of Foxp3 and CTLA-4, cells were first stained for surface molecules and subsequently fixed, permeabilized and stained with the corresponding mAbs (eBioscience). Cells were assayed using a Beckman Coulter FCM (Beckman Coulter, Fullerton, CA, USA), and data were analyzed with CXP v2.2 software (Beckman Coulter). 1 T-cell isolation kit and FCM sorting. According to the manufacturer's instruction, erythrocyte-depleted splenocytes from control and diabetic mice were suspended in phosphate-buffered saline containing 0.5% bovine serum albumin and 2 mM EDTA (pH 7.2) and then incubated with a biotin-antibody cocktail against CD8 (Ly2), CD11b (membraneactivated complex 1), CD45R (B220), CD49B (DX5) and Ter-119 for 20 min at 4 uC. Microbead-conjugated, antibiotin mAbs (Clone Bio318E7.2) was then added to deplete non-CD4 1 T cells. The cell suspension was loaded on an LD column placed in the magnetic field of a magnetic-activated cell-sorting separator to allow unlabeled CD4
CD4
1 T cells to run through the colomn. For further isolation of CD4 Tregs were subsequently added to each well. After the 24-h incubation, 0.5 mg/ml anti-BrdU was added to each well for additional 16-18 h. Eu flurorescence was measured using a time-resolved fluorometer as describe above.
2 T cells from Foxp3-GFP knock-in mice or control and diabetic mice were isolated as describe above. CD4
1 CD25 2 T cells ( 2310 5 ) were cultured in the presence of plate-bound anti-CD3 mAbs (2 mg/ml) and soluble anti-CD28 mAbs (1 mg/ml) with or without TGF-b (5 ng/ml). At indicated time points, cells were collected and stained for Foxp3 as describe above.
Statistical analysis
Results were expressed as mean6s.d. values. Statistical analysis was performed using Student's t-test for all experiments. Statistical significance was assigned for P values ,0.05.
RESULTS
The proportion of CD4 2 Teffs in peripheral blood lymphocytes (PBLs), the spleen, peripheral lymph nodes (pLNs) and mesenteric LNs (mLNs) 10 days, 1 month and 4 months after the onset of diabetes. The fractions of both CD4
1 T cells and CD8
1 T cells in PBLs gradually decreased in STZ-induced diabetic mice (P,0.01; Figure 1a ). However, the frequency of
Tregs, out of the total CD4 1 T-cell population, was significantly increased by 4 months after the onset of diabetes (P,0.01; Figure 1b ), whereas the proportions of CD4
1 CD25 1 Tregs in the periphery were still normal at the early time points. To further characterize CD4
1 CD25 1 Tregs, we used Foxp3 as a marker for CD4 1 CD25 1 Tregs because it plays a critical role in their 1 T cells, was significantly increased only at 4 months after the onset of diabetes (P,0.01; Figure 1c ).
As shown in Figure 2 , the total number of splenocytes and the percentage of CD4 1 T cells but not CD8 1 T cells was decreased in diabetic B6 mice by 4 months (P,0.001, and P,0.01, respectively; Figure 2b ). However, the percentage of CD4 Tregs from the spleens of these mice and evaluated the expression of CD62L, CD44, CD45RB and GITR, as well as intracellular CTLA-4 and Foxp3 expression by fluorescence-activated cell sorting. Naive T cells express high levels of CD62L and CD45RB and low levels of CD44, whereas activated/memory T cells express high levels of CD44 and low levels of CD62L and CD45RB. These molecules also play important roles in CD4 1 CD25 1 Tregs. As shown in Figure 4 , we found identical expression of Foxp3 on CD4 
Foxp3
1 Tregs was increased in the pLNs and mLNs of diabetic mice. Lymphocytes from pLNs and mLNs were freshly prepared at 10 days, 1 month and 4 months after the onset of diabetes and stained for CD4, CD8, CD25 and Foxp3. 1 Tregs from diabetic mice demonstrated a significantly reduced suppressive ability (P,0.05, P,0.01 and P,0.001, respectively; Figure 5a and b) .
Conversely, it was reported that Teffs in diabetic NOD mice were resistant to regulation by CD4 Figure 6 , insulin administration reversed the effect of hyperglycemia on the proportion of CD4 1 CD25 1 Foxp3 1 Tregs out of total CD4 1 T cells in PBLs, splenocytes, pLNs and mLNs of diabetic mice (Figure 6a-d Figure 3) . These data indicate that hyperglycemia contributed to the frequency, phenotype and functional changes of CD4
Tregs from mice with long-term STZ-induced diabetes. 
CD25
2 T cells isolated from control B6 mice were used as responder cells and were cultured with mitomycin C-pretreated allogeneic BALB/c splenocytes in the presence of CD4 
1 Tregs from diabetic mice at the indicated ratios. The gray column represents control responders without CD4 1
1 Tregs. Data are shown as mean6s.d. (n55), for one representative out of three independent experiments. *P,0.05, **P,0.01 and ***P,0.001, comparison was between the indicated groups. mAb, monoclonal antibody; MLR, mixed lymphocyte reaction; TCR, T-cell receptor; Teff, effector T cell; Treg, T regulatory cell.
Effects of hyperglycemia on CD4
1 T-cell subsets in mice 1 Treg development in the thymus during diabetes progression. The total number of thymocytes was significantly decreased at 1 and 4 months after the onset of diabetes, respectively (P,0.05 and P,0.001; Figure 7a ). However, there was no significant change in the percentages of CD4 single positive (CD4SP), CD8SP, CD4CD8 double positive and CD4CD8 double negative cells in the thymuses of diabetic mice (Figure 7b) . Nevertheless, the proportions of CD25 1 or Foxp3 1 nTregs among all CD4SP cells were significantly increased beginning 1 month after the onset of diabetes (P,0.05; Figure 7c and d). Helios is a newly discovered molecule that is mainly expressed on thymus-produced CD4 1 CD25 1 nTregs in mice and humans. 24, 25 Consistent with the changes of CD4 1 CD25 1 Tregs observed in the thymus, the frequency of CD4
1 Helios 1 Foxp3 1 nTregs was significantly enhanced in PBLs, the spleen, pLNs and mLNs in mice that had STZ-induced diabetes for 4 months (P,0.05, P,0.01 and P,0.001, respectively; Figure 8 ). Conversely, the frequency of CD4
1 Helios 2 Foxp3 1 iTregs, which may represent peripherally induced iTregs, was significantly enhanced in the spleen, pLNs and mLNs of diabetic mice (P,0.05, P,0.01 and P,0.001, respectively; Figure 8 ). These data collectively indicate that both the enhanced output of CD4 
CD25
2 T cells from Foxp3-GFP knock-in mice to investigate the effect of glucose on the induction of CD4
Foxp3
1 iTregs in vitro. As shown in Figure 9 , along with anti-CD3/CD28 mAbs and TGF-b stimulation, the increased glucose concentration significantly enhanced the percentage and absolute number of CD4 
1 iTregs (Figure 9a-c) . We also studied the effect of glucose on the induction of CD4 1
1 iTregs using purified CD4 
CD25
2 T cells from mice with long-term hyperglycemia were more sensitive to differentiate into CD4
1
Foxp3
1 iTregs than those from control mice. 
CD25
1 Tregs in the spleen. Data are shown as mean6s.d. (n56), for one representative out of two independent experiments. *P,0.05, **P,0.01 and ***P,0.001, comparison was among the indicated groups. CTLA-4, cytotoxic T lymphocyte-associated antigen 4; FACS, fluorescenceactivated cell sorting; GITR, glucocorticoid-induced tumor-necrosis factor receptor; mLN, mesenteric lymph node; PBL, peripheral blood lymphocyte; pLN, peripheral lymph node; Treg, T regulatory cell.
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DISCUSSION
In this study, we demonstrated that the percentages of CD4 1 CD25 Tregs appeared normal at the onset of diabetes and gradually increased after the establishment of STZ-induced diabetes, we concluded that CD4 1 CD25 1 Tregs might not be involved in the initiation of disease in this model, however, CD4 1 CD25 1 Tregs are altered under long-term diabetic conditions in this model. In order to figure out whether high glucose levels play a role in altering CD4
1 CD25 1 Tregs, we treated diabetic mice with insulin to maintain blood glucose at normal levels. The changes in CD4 1 CD25 1 Treg frequency, phenotype and function under hyperglycemic conditions were all reversed with insulin treatment. This supports the hypothesis that long-term hyperglycemia caused a series of changes in the CD4 1 CD25 1 Treg population in mice with long-term STZ-induced diabetes. However, we cannot exclude the possibility that stress and an altered neuroendocrine system impaired T-cell subsets in these mice. We explored the origin of the increased proportion of CD4 1 CD25
1
Tregs in the periphery of mice with STZ-induced diabetes. Similar to the changes in the periphery, the percentage of CD4 1 CD25 1 nTregs in the thymus was also gradually increased following the onset of diabetes. By 1 month after the onset of diabetes, the proportion of CD4 1 CD25 1 nTregs in the thymus was significantly elevated. A previous report showed that STZ may be toxic to the thymus; 26 however, Mic et al. 27 provided conflicting results. Our data showed normal T-cell development and no alteration in CD4 1 CD25 1 Tregs in the thymus 10 days after the onset of diabetes. Moreover, insulin injections reversed the alterations in thymic CD4
1 CD25 1 nTregs in diabetic mice. These data indicate that STZ did not affect T-cell development directly, but STZ-induced hyperglycemia or other relevant changes impacted thymic CD4 , which is a summary of four independent experiments. *P,0.05, **P,0.01 and ***P,0.001, compared with the control mice. DN, double negative; DP, double positive; FACS, fluorescence-activated cell sorting; nTreg, naturally occurring regulatory T cell.
Effects of hyperglycemia on CD4
1 T-cell subsets in mice [29] [30] [31] [32] [33] It was reported that high glucose levels promoted an increased production of TGF-b1 from human mesenchymal stem cells. 34, 35 The activated protein kinase C-mitogen-activated protein kinase signaling pathway leads to high expression of TGF-b and contributes to diabetic nephropathy in diabetic mice. 1, 36 The IL-2-STAT5 signaling pathway is essential for CD4 1 CD25 1 iTreg induction. 37, 38 Some reports demonstrated defective IL-2 production in T1D patients or NOD mice. 12, 39 In our STZ-induced diabetic mouse model, CD4
1 CD25 2 Teffs produced significantly more IL-2 after stimulation with phorbol myristate acetate and ionomycin. These data collectively suggest that enhanced TGF-b and IL-2 production may at least partially contribute to peripheral CD4 1 CD25 1 iTreg induction in mice with long-term diabetes. Therefore, hyperglycemia impacts both thymic and peripheral CD4 , for one representative out of three independent experiments. *P,0.05, **P,0.01 and ***P,0.001, compared with the indicated groups. FACS, fluorescence-activated cell sorting; iTreg, inducible regulatory T cell; mLN, mesenteric lymph node; nTreg, naturally occurring regulatory T cell; PBL, peripheral blood lymphocyte; pLN, peripheral lymph node; SPL, splenic-derived lymphocyte.
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